AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) reported Q2 2017 earnings this Morning, coming in at ($0.40) per share, missing Wall Street’s estimates of $1.34 per Share. Revenue for the quarter came in at $158.39 million missing the streets estimates of $158.83 million
Analyst Coverage For AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
These are 1 Sell Rating, 9 Hold Ratings, 2 Buy Ratings .
The current consensus rating for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is Hold (Score: 2.08) with a consensus target price of $28.70 , a potential (52.66% upside)Recent Insider Trading for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
- On 7/13/2017 Julie Krop, SVP, sold 4,938 with an average share price of $20.00 per share and the total transaction amounting to $98,760.00.
- On 5/1/2017 Julie Krop, SVP, sold 1,891 with an average share price of $24.45 per share and the total transaction amounting to $46,234.95.
- On 10/20/2016 Julie Krop, SVP, sold 4,938 with an average share price of $24.80 per share and the total transaction amounting to $122,462.40.
- On 11/10/2015 John A Fallon, Director, bought 3,230 with an average share price of $31.20 per share and the total transaction amounting to $100,776.00.
- On 10/1/2015 William K Heiden, CEO, sold 2,000 with an average share price of $39.69 per share and the total transaction amounting to $79,380.00.
- On 9/1/2015 William K Heiden, CEO, sold 2,000 with an average share price of $61.19 per share and the total transaction amounting to $122,380.00.
Recent Trading for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Shares of AMAG Pharmaceuticals, Inc. closed the previous trading session at 18.73 down -0.07 -0.40% with 794,736 shares trading hands.